444 related articles for article (PubMed ID: 21839683)
1. Biological activities of HDL subpopulations and their relevance to cardiovascular disease.
Camont L; Chapman MJ; Kontush A
Trends Mol Med; 2011 Oct; 17(10):594-603. PubMed ID: 21839683
[TBL] [Abstract][Full Text] [Related]
2. Antiatherogenic small, dense HDL--guardian angel of the arterial wall?
Kontush A; Chapman MJ
Nat Clin Pract Cardiovasc Med; 2006 Mar; 3(3):144-53. PubMed ID: 16505860
[TBL] [Abstract][Full Text] [Related]
3. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
Kontush A; Chapman MJ
Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
[TBL] [Abstract][Full Text] [Related]
4. [The biological activity of high-density lipoprotein fractions and their role in the development of cardiovascular diseases].
Babintseva YD; Camont L; Chapman J; Lhomme M; Karagodin VP; Kontush A; Orekhov AN
Ter Arkh; 2016; 88(9):111-118. PubMed ID: 28635814
[TBL] [Abstract][Full Text] [Related]
5. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities.
Kontush A; Chapman MJ
Curr Opin Lipidol; 2010 Aug; 21(4):312-8. PubMed ID: 20581677
[TBL] [Abstract][Full Text] [Related]
6. Should we routinely measure low-density and high-density lipoprotein subclasses?
Rizzo M; Berneis K; Zeljkovic A; Vekic J
Clin Lab; 2009; 55(11-12):421-9. PubMed ID: 20225664
[TBL] [Abstract][Full Text] [Related]
7. Inflammation alters HDL composition and function: implications for HDL-raising therapies.
Marsche G; Saemann MD; Heinemann A; Holzer M
Pharmacol Ther; 2013 Mar; 137(3):341-51. PubMed ID: 23246719
[TBL] [Abstract][Full Text] [Related]
8. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
Vaziri ND
J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral contraceptives on lipid metabolism.
Krauss RM
J Reprod Med; 1986 Jun; 31(6 Suppl):549-50. PubMed ID: 3723487
[TBL] [Abstract][Full Text] [Related]
10. [Postprandial hyperlipidemia, small and dense LDL, HDL sub-fractions].
Braschi S
Ann Med Interne (Paris); 2001 Apr; 152(3):162-8. PubMed ID: 11431575
[TBL] [Abstract][Full Text] [Related]
11. Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research.
Triolo M; Annema W; Dullaart RP; Tietge UJ
Biomark Med; 2013 Jun; 7(3):457-72. PubMed ID: 23734809
[TBL] [Abstract][Full Text] [Related]
12. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.
Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K
Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506
[TBL] [Abstract][Full Text] [Related]
13. The rationale for using apoA-I as a clinical marker of cardiovascular risk.
Barter PJ; Rye KA
J Intern Med; 2006 May; 259(5):447-54. PubMed ID: 16629850
[TBL] [Abstract][Full Text] [Related]
14. Signaling by the high-affinity HDL receptor scavenger receptor B type I.
Saddar S; Mineo C; Shaul PW
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):144-50. PubMed ID: 20089950
[TBL] [Abstract][Full Text] [Related]
15. HDL particle subpopulations: Focus on biological function.
Rached FH; Chapman MJ; Kontush A
Biofactors; 2015; 41(2):67-77. PubMed ID: 25809447
[TBL] [Abstract][Full Text] [Related]
16. Lipid and lipoprotein metabolism in chronic kidney disease.
Kaysen GA
J Ren Nutr; 2009 Jan; 19(1):73-7. PubMed ID: 19121776
[TBL] [Abstract][Full Text] [Related]
17. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
Chapman MJ; Guérin M; Bruckert E
Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
[TBL] [Abstract][Full Text] [Related]
18. Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation.
Gómez Rosso L; Lhomme M; Meroño T; Sorroche P; Catoggio L; Soriano E; Saucedo C; Malah V; Dauteuille C; Boero L; Lesnik P; Robillard P; John Chapman M; Brites F; Kontush A
Atherosclerosis; 2014 Dec; 237(2):652-60. PubMed ID: 25463101
[TBL] [Abstract][Full Text] [Related]
19. Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.
Estrada-Luna D; Ortiz-Rodriguez MA; Medina-Briseño L; Carreón-Torres E; Izquierdo-Vega JA; Sharma A; Cancino-Díaz JC; Pérez-Méndez O; Belefant-Miller H; Betanzos-Cabrera G
Molecules; 2018 Oct; 23(11):. PubMed ID: 30360466
[TBL] [Abstract][Full Text] [Related]
20. Beginning to understand high-density lipoproteins.
Santos-Gallego CG; Badimon JJ; Rosenson RS
Endocrinol Metab Clin North Am; 2014 Dec; 43(4):913-47. PubMed ID: 25432389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
